AlloSource® Recognized With 2023 Cigna Healthy Workforce™ Designation


Centennial, Colo. – February 22, 2024 – Cigna has selected AlloSource as a recipient of their Gold level Healthy Workforce Designation for demonstrating a strong commitment to improving the health and vitality of its employees through a workplace well-being program. This is a significant…


AlloSource Announces First Implant Of AceConnex™ Pre-Sutured Fascia Device In Hip Labral Reconstruction Procedure


Pre-sutured fascia allograft designed for hip arthroscopists to help the surgeon increase their procedure efficiency and return their patients to an active lifestyle  Centennial, Colo. — November 8, 2023 — AlloSource®, one of the largest allograft providers creating innovative tissue products to…


AlloSource Announces First Patient Implantation in United Kingdom Clinical Evaluation of ProChondrix CR Cryopreserved Osteochondral Allograft


Centennial, Colo. — October 31, 2023 — AlloSource®, one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced the first patient implantation of ProChondrix® CR Cryopreserved Osteochondral Allograft in a United Kingdom (UK) independent…


AlloSource Announces Poster Featuring Prochondrix CR Osteochondral Allograft Clinical Outcomes at the 17th International Cartilage Regeneration & Joint Preservation Society (ICRS) World Congress


Centennial, Colo. — September 8, 2023 — AlloSource®, one of the United States leading innovators and manufacturers of cartilage for joint preservation, today announced that its research on positive prospective clinical outcomes for the repair of focal articular cartilage defects in the knee using…


AlloSource Receives FDA 510(k) Clearance for AceConnex™ Pre-Sutured Fascia for Hip Labral Reconstruction and Augmentation


Centennial, Colo. — July 11, 2023 — AlloSource®, one of the largest allograft providers creating innovative cellular and tissue products to help surgeons heal their patients, today announced the U.S. Food and Drug Administration’s 510(k) clearance of AceConnex Pre-Sutured Fascia for hip labral…


Study on ProChondrix Osteochondral Allograft Published in the Journal of Orthopaedic Surgery Demonstrates Encouraging Outcomes When Used on Isolated Articular Cartilage Defects


Centennial, Colo. — June 29, 2023 — AlloSource®, a leading innovator and manufacturer of cartilage for joint preservation, today announced the Journal of Orthopaedic Surgery published the study titled “Short term clinical outcomes of a ProChondrix® thin laser-etched osteochondral allograft for the…


AlloSource Launches AlloMend Duo Acellular Dermal Matrix, A Natural Solution For Non-Directional Implantation in Soft Tissue Reconstruction


Centennial, Colo. — May 25, 2023 — AlloSource®, one of the largest nonprofit allograft providers in the U.S. creating innovative cellular and tissue products to help surgeons heal their patients, today announced the launch of AlloMend® Duo Acellular Dermal Matrix (ADM), a natural solution for soft…


ProChondrix CR, AlloSource’s Novel Laser Etched Cryopreserved Osteochondral Allograft, Shows Positive Patient-Reported Outcomes in Prospective Clinical Study on Focal Articular Cartilage Defects in the Knee


Centennial, Colo. — March 8, 2023 — AlloSource®, one of the largest allograft providers creating innovative cellular and tissue products to help surgeons heal their patients, today announced positive prospective clinical outcomes for the repair of focal articular cartilage defects in the knee using…


AlloSource Recognized with Cigna Healthy Workforce Designation


Centennial, Colo. – February 10, 2023 – Cigna has selected AlloSource as a recipient of their Bronze level Healthy Workforce Designation for demonstrating a strong commitment to improving the health and well-being of its employees through a workplace wellness program. AlloSource’s program looks at…


AlloSource Announces Dean Elliott as New President and CEO


Centennial, Colo. — October 19, 2022 — AlloSource, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, announced today AlloSource Chief Operating and Legal Officer, Dean Elliott, has been selected as the…


AlloSource Announces Award from the U.S. Government to Supply Allograft Skin for Crisis Preparedness in the Event Of Mass Casualty Burn Incidents


Centennial, Colo. — October 12, 2022 — AlloSource®, one of the largest allograft providers in the U.S., today announced it was awarded a multi-year contract by the Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response…


AlloSource Announces New Partnership with St. Mary’s Grand Junction as Part of its Placenta Donation Program


Centennial, Colo. — September 26, 2022 — AlloSource, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, is proud to announce the expansion of its AlloSource Placental Donation Program into Grand Junction,…


Dr. Todd Huzar Recognized By Allosource With The Annual Dr. Steven Gitelis Inspiration Award For His Work With Burn Survivors


Centennial, Colo. — August 30, 2022 — Burn Surgeon Dr. Todd Huzar was recognized by AlloSource®, one of the largest allograft providers in the U.S., with its sixth annual Dr. Steven Gitelis Inspiration Award, which honors a physician who understands and embraces the use of donated human tissue,…


AlloSource Announces President and CEO Retirement


Centennial, Colo. — August 2, 2022 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced President and CEO, Tom Cycyota, plans to retire. Cycyota has been in his role since 2000,…


AlloSource® Adds Quadricep Tendons To Its AlloConnex™ Line Of Tendons, Ligaments And Fascia


Centennial, Colo. — July 12, 2022 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced the addition of a quadricep tendon to its AlloConnex™ line of tendons, ligaments and fascia.…


AlloSource® Announces New Micro Fibers Demineralized Bone Allograft


Centennial, Colo. — June 28, 2022 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced the addition of AlloFuse® Micro Fibers Demineralized Bone allograft for use in spinal, foot…


AlloSource Sponsored DeVaughn Levy-Hagan Memorial Basketball Game Raises Money For Mental Health/Suicide Prevention


Centennial, Colo. — April 27, 2022 — AlloSource®, Colorado’s largest homegrown bioscience company whose business focuses on creating innovative cellular and tissue allografts to help surgeons heal their patients, sponsored the DeVaughn Levy-Hagan Memorial Basketball Game for Mental Health/Suicide…


Allosource Recognized As The Top Colorado Bioscience Manufacturer


Centennial, Colo. — April 12, 2022 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, has been recognized as 2022 Bioscience Manufacturer of the Year by CompanyWeek’s Colorado Manufacturing Awards…


AlloSource’s Cartilage Allograft Expertise To Be Featured At The International Cartilage Regeneration & Joint Preservation Society Annual Meeting


Centennial, Colo. — April 5, 2022 — AlloSource®, one of the largest allograft providers creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced scientific data supporting the company’s cartilage allograft technology will be featured at the…


AlloSource Launches AlloMend Extra-Large Acellular Dermal Matrix – New Dermal Graft has the Largest Footprint Within the AlloMend Product Line to Support Demanding Soft Tissue Applications in Plastic and Reconstructive Surgery


Centennial, Colo. — October 27, 2021 — AlloSource®, one of the largest allograft providers in the U.S. creating innovative cellular and tissue products to help surgeons heal their patients, today announced the launch of AlloMend® Extra-Large (XL) Acellular Dermal Matrix (ADM), the newest addition…


AlloSource Launches AlloMend Ultra-Thick Acellular Dermal Matrix New Allograft Is The Thickest In The AlloMend Product Line To Support Demanding Soft Tissue Applications


Centennial, Colo. — August 11, 2021 — AlloSource®, one of the largest allograft providers in the U.S. creating innovative cellular and tissue products to help surgeons heal their patients, today announced the launch of AlloMend® Ultra-Thick Acellular Dermal Matrix (ADM), the newest addition to the…


AlloSource Honors Dr. David Argo With The Annual Dr. Steven Gitelis Inspiration Award


Centennial, Colo. — June 9, 2021 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, today announced it is awarding Dr. David Argo with its fifth annual Dr. Steven Gitelis Inspiration Award. The…


Study On The Biomechanical Properties of Dermal Matrices Published In Plastic And Reconstructive Surgery—Global Open Finds AlloSource’s Meshed AlloMend Has Superior Fluid Egress Properties


Centennial, Colo. — June 2, 2021 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, today announced Plastic and Reconstructive Surgery—Global Open published the findings of a study titled “The…


AlloSource Announces First Patients Implanted With AlloWrap Amniotic Membrane In Clinical Study For Two-Level Anterior Cervical Discectomy And Fusion Procedures


Centennial, Colo. — February 23, 2021 — AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced the first patients have been enrolled in its clinical study titled, A Randomized, Controlled Study to Evaluate Effectiveness of…